Treatment Interruption after Pregnancy: Effects on Disease Progression and Laboratory Findings

Table 2

Difference in slope and P-values between women stopping or continuing therapy after delivery, according to antiretroviral therapy use during pregnancy.

	All women		ZDV monotherapy		Combination therapy
Parameter	2–6 months	6–12 months	2–6 months	Parameter	2–6 months	6–12 months
CD4 count	−12.2, 𝑃=.51	10.0, 𝑃=.46	−19.5, 𝑃=.52	CD4 count	−12.2, 𝑃=.51	10.0, 𝑃=.46
CD4+ %	−0.01, 𝑃=.96	−0.13, 𝑃=.46	0.06, 𝑃=.82	CD4+ %	−0.01, 𝑃=.96	−0.13, 𝑃=.46
Log10 HIV RNA	−0.07, 𝑃=.35	−0.04, 𝑃=.43	−0.10, 𝑃=.25	Log10 HIV RNA	−0.07, 𝑃=.35	−0.04, 𝑃=.43